Search
Butyrfentanyl
go.drugbank.com/drugs/DB09173ExperimentalIllicit[A182054] It is an analog of [fentanyl] with roughly 1/30 the potency.[L7811] Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic. … [L7811] Butyrfentanyl has no current legitimate clinical applications, but anecdotal reports indicate it may occasionally be surfacing on the grey-market as a recreational drug.
Chlormadinone acetate
go.drugbank.com/drugs/DB15903ApprovedWithdrawnIn the US, chlormadinone acetate was formerly marketed as a component of the combination drug products Estalor-21 and C-Quens.
Icotinib
go.drugbank.com/drugs/DB11737Investigational. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc
Daclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnHepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … The same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis.
Irofulven
go.drugbank.com/drugs/DB05786InvestigationalMGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis. … ” status by the U.S.
Metixene
go.drugbank.com/drugs/DB00340ApprovedMetixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.
Aminophenazone
go.drugbank.com/drugs/DB01424ApprovedWithdrawnAminophenazone is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties that carries a risk of agranulocytosis. In biomedical applications, radiolabelled (13C-labeled) aminophenazone has been used in breath tests to ...
RTP-801i
go.drugbank.com/drugs/DB06048InvestigationalRTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801.
SGS-742
go.drugbank.com/drugs/DB05010InvestigationalSGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.